Horses are exquisitely sensitive to tetanus neurotoxin and are exposed to the risk of infection with throughout life. The vaccine against tetanus is highly effective at preventing disease, whereas tetanus in unvaccinated populations is associated with high mortality rates. Current guidelines in New Zealand and Australia for the available vaccine contain contradictions and limitations surrounding the optimal tetanus immunisation protocols for both adult horses and foals. This review critically evaluates the scientific literature on tetanus prophylaxis in horses within the context of equine practice and available products in New Zealand and Australia. The review was conducted by a panel of industry and specialist veterinarians to obtain agreement on nine equine tetanus prophylaxis guidelines for practising veterinarians. The primary protocol for tetanus toxoid (TT) immunisation consists of a three-dose series IM for all horses ≥ 6 months of age, and a four-dose series IM is proposed if commencing vaccination in foals between 3 and 6 months of age. Tetanus prophylaxis in foals < 3 months of age relies on passive immunity strategies. Following the completion of the primary protocol, a TT booster dose IM should be administered within 5 years, and every 5 years thereafter. When followed, these protocols should provide adequate protection against tetanus in horses. Additional tetanus prophylaxis guidelines are provided for veterinarians attending a horse experiencing a known "risk event" (e.g. wound, hoof abscess, surgery, umbilical infection). When a correctly vaccinated horse experiences a risk event, pre-existing immunity provides protection against tetanus. When an unvaccinated horse or one with unknown vaccination status, or a foal born to an unvaccinated dam, experiences a risk event, TT IM and tetanus antitoxin (TAT) 1,500 IU SC should be administered simultaneously at separate sites, and the TT primary immunisation protocol should subsequently be completed for the horse's respective age. In previously immunised pregnant broodmares, a TT booster dose administered 4-8 weeks prior to parturition optimises the transfer of passive immunity against tetanus to the newborn foal via colostrum; provided that post-natal IgG concentration in serum is > 800 mg/dL (8 g/L), such foals should be passively protected against tetanus up to 6 months of age. Survivors of clinical tetanus must still receive the primary protocol for vaccination against tetanus. In summary, all horses in New Zealand and Australia should be vaccinated against tetanus with protection maintained throughout life via TT booster doses, facilitated by accurate medical record keeping and client education.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00480169.2024.2365283DOI Listing

Publication Analysis

Top Keywords

tetanus prophylaxis
20
tetanus
18
zealand australia
16
months age
16
primary protocol
12
prophylaxis horses
8
guidelines zealand
8
tetanus unvaccinated
8
prophylaxis guidelines
8
foals months
8

Similar Publications

Introduction: Tetanus, caused by , poses a life-threatening risk by affecting the nervous system and inducing muscle tightness. The objective of this study is to examine the knowledge, attitudes, and behaviors of non-medical university students regarding the tetanus vaccine in the context of post-road accidents.

Methods: A descriptive cross-sectional study was conducted in 2023, involving 378 students from non-medical disciplines, primarily from information technology, business administration, and engineering faculties, with a mean age of 20.

View Article and Find Full Text PDF

Maternal immunization is a valuable tool for protecting mother and unborn child from vaccine-preventable diseases. However, the implementation of strategies for vaccinating pregnant women has only recently gained traction. This work is aimed at providing an overview of European vaccination strategies and gathering evidence on interventions enhancing vaccination knowledge, attitudes, and behaviors (KAB) in pregnant women.

View Article and Find Full Text PDF

Background: Immunisation in pregnancy against pertussis can reduce severe disease in infancy. There are few data on the safety and immunogenicity of vaccines given to pregnant women living with HIV and their infants. We aimed to describe the safety and immunogenicity of a tetanus-diphtheria-acellular pertussis (TdaP) vaccine containing genetically detoxified pertussis toxin given to pregnant women living with HIV and the effect of the vaccine on infant whole-cell pertussis vaccine responses.

View Article and Find Full Text PDF

[Diphtheria-tetanus-pertussis vaccine mortality].

Ugeskr Laeger

December 2024

Mikkelborg Alle, Hørsholm.

Although the diphtheria-tetanus-pertussis (DTP) vaccine is lifesaving through decades, it has been voiced that the vaccine is associated with 50% increase in mortality, an alleged negative non-specific vaccine effect prone to girls. Post hoc analyses of historical observational data supporting the hypothesis of the DTP vaccine having detrimental effects have never been replicated in low- or high-income countries. An RCT in Guinea-Bissau found fewer deaths with DTP vaccine than without.

View Article and Find Full Text PDF

Background: The childhood immunization coverage in Serbian communities in Kosovo after the 1999 armed conflict has not been investigated. The study purpose was to evaluate the trend of immunization coverage with vaccines from the national childhood immunization program in Serbian communities in Kosovo and Metohija from 2003 to 2022.

Methods: Data were retrieved from the annual reports of the Public Health Institute of Kosovska Mitrovica received through notifications from the primary health centers where vaccines are being administered.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!